954397-98-9

Upstream product

• 954382-59-3 1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazole-4-carboxylic acid 
• 954397-86-5 methyl 3-(1-piperazinyl)-1-naphthoate trifluoroacetate 
• 104-85-8 para-methylbenzonitrile 
• 621-33-0 m-phenetidine 
• 954382-60-6 N-(3-ethoxyphenyl)-4-methylbenzamidine 
• 954382-61-7 ethyl 1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazole-4-carboxylate 

Downstream Products

• 954397-96-7 3-(4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-1-piperazinyl)-1-naphthoic acid trifluoroacetate 
• 954397-95-6 3-{4-[1-(3-ethoxyphenyl)-2-p-tolyl-1H-imidazole-4-carbonyl]piperazin-1-yl}naphthalene-1-carboxylic acid 

Relevant academic research and scientific papers

Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators

Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

A rapid, large-scale synthesis of a potent cholecystokinin (CCK) 1R receptor agonist

The development of a scalable synthesis of a potent cholecystokinin (CCK) IR receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support